2 Information about dupilumab

Marketing authorisation indication

Dupilumab (Dupixent, Sanofi Genzyme) is indicated for the 'treatment of moderate to severe atopic dermatitis in adults who are candidates for systemic therapy'.

Dosage in the marketing authorisation

The recommended dose, given by subcutaneous injection, is initially 600 mg (2×300‑mg injections), followed by 300 mg given every other week. It can be used with or without topical corticosteroids. Topical calcineurin inhibitors may be used, but should be reserved for problem areas only, such as the face, neck, intertriginous and genital areas. "Consideration should be given to discontinuing treatment in patients who have shown no response after 16 weeks of treatment". Some patients whose disease shows partial response may subsequently improve with continued treatment beyond 16 weeks.


£1,264.89 per pack of 2×2‑ml syringes of 150 mg/1 ml solution (excluding VAT; British national formulary online, accessed March 2018).

The company has a commercial arrangement. This makes dupilumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)